Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial

202510 citationsJournal Articlehybrid Open Access

Authors

Alison Luckey

Manica Balasegaram · Global Antibiotic Research & Development Partnership

Lindley A. Barbee · University of Washington

Teresa A. Batteiger · Indiana University School of Medicine

Helen Broadhurst

Stephanie E. Cohen · San Francisco Department of Public Health

Sinead Delany‐Moretlwe · University of the Witwatersrand

Henry J.C. de Vries

Abstract

German Federal Ministry of Research, Technology and Space, UK Department of Health and Social Care as part of the Global Antimicrobial Resistance Innovation Fund, Japan Ministry of Health, Labour and Welfare, Netherlands Ministry of Health, Welfare and Sport and Directorate-General for International Cooperation, Switzerland Federal Office of Public Health, and the Canton of Geneva, Switzerland.

Topics & Keywords

Reproductive tract infections research Coccidia and coccidiosis research Herpesvirus Infections and Treatments

Publication Details

Published in: The Lancet

Volume 407, Issue 10524, pp. 147-160

DOI: 10.1016/s0140-6736(25)01953-1

Field-Weighted Citation Impact: 12.35

Command Palette

Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial

Authors

Abstract

Topics & Keywords

Publication Details